Chalkis Health Industry Co., Ltd Logo

Chalkis Health Industry Co., Ltd

000972.SZ

(1.0)
Stock Price

2,92 CNY

7.15% ROA

42.76% ROE

28.33x PER

Market Cap.

2.321.564.840,00 CNY

199.97% DER

0% Yield

15.51% NPM

Chalkis Health Industry Co., Ltd Stock Analysis

Chalkis Health Industry Co., Ltd Fundamental Analysis

Fundamental analysis in stock investing is like studying the foundation of a house before buying it. It involves looking at a company's financial health, like its earnings, assets, and debts, to determine if it's a good investment based on its fundamental strength and potential for growth.

Chalkis Health Industry Co., Ltd Fundamental Stock Analysis
# Analysis Rating
1 ROE

ROE surpassing expectations (78.17%) highlights strong profitability and efficient use of shareholders' equity, making it an appealing investment prospect.

2 ROA

The stock's ROA (6.61%) shows that it's doing a pretty good job at making money from its assets, making it a solid choice to invest and earn steady profits.

3 Assets Growth

Over the past three years, this company's revenue has consistently grown, demonstrating a positive financial trend that makes it an appealing choice.

4 PBV

The stock's elevated P/BV ratio (19.92x) raises concerns about its overvaluation, making it an imprudent choice for investors seeking value.

5 DER

The stock is burdened with a heavy load of debt (345%), making it financially unstable and potentially risky for investors.

6 Revenue Growth

Company has experienced no growth in revenue over the past three years, suggesting limited profitability and making it a less desirable investment opportunity.

7 Net Profit Growth

Despite the passage of five years, this company's net profit has not shown any improvement, highlighting a lack of growth and making it a less appealing investment prospect.

8 Graham Number

The company's Graham number indicates that it is overvalued compared to its stock price, suggesting a potentially unfavorable investment opportunity.

9 Dividend Growth

Potential investors should be aware that the company's dividend growth has shown no upward trend in the past three years, indicating limited potential for increased returns.

10 Dividend

The company's decision to withhold dividends for three years raises questions about its ability to generate consistent returns.

11 Buffet Intrinsic Value

Based on Warren Buffett's formula, the company's stock seems overpriced (-252), indicating a potential drawback for investors as its market price exceeds its estimated intrinsic value.

Chalkis Health Industry Co., Ltd Technical Analysis

Technical analysis in stock investing is like reading the patterns on a weather map to predict future weather conditions. It involves studying past stock price movements and trading volumes to make predictions about where a stock's price might go next, without necessarily looking at the company's financial health.

Chalkis Health Industry Co., Ltd Technical Stock Analysis
# Analysis Recommendation
1 Awesome Oscillator Hold
2 MACD Buy
3 RSI Hold
4 Stoch RSI Sell

Chalkis Health Industry Co., Ltd Price Chart

Financial Statements

Financial statements are like report cards for companies. They show how much money a company makes (income statement), what it owns and owes (balance sheet), and where it spends its money (cash flow statement), helping stock investors understand if a company is healthy and worth investing in.

Income Statements

An income statement for a company is like a scoreboard for its profits and losses. It shows how much money the company made (revenue) and how much it spent to make that money (expenses), helping stock investors see if a company is making a profit or not.

Revenue in stock investing is the total amount of money a company earns from its sales, and it's a key factor that investors consider to assess a company's financial performance and growth potential.

Chalkis Health Industry Co., Ltd Revenue
Year Revenue Growth
1997 239.929.584
1998 360.952.504 33.53%
1999 392.197.687 7.97%
2000 467.575.925 16.12%
2001 549.272.557 14.87%
2002 676.764.818 18.84%
2003 948.826.906 28.67%
2004 695.720.073 -36.38%
2005 1.030.318.949 32.48%
2006 1.532.717.753 32.78%
2007 2.142.790.115 28.47%
2008 1.967.529.628 -8.91%
2009 1.660.020.991 -18.52%
2010 1.511.963.570 -9.79%
2011 1.424.785.535 -6.12%
2012 1.245.962.132 -14.35%
2013 954.944.330 -30.47%
2014 416.772.255 -129.13%
2015 682.896.707 38.97%
2016 588.176.013 -16.1%
2017 517.710.604 -13.61%
2018 626.669.589 17.39%
2019 213.188.826 -193.95%
2020 22.966.067 -828.28%
2021 174.451.612 86.84%
2022 589.285.550 70.4%
2023 220.544.638 -167.2%
2023 569.484.113 61.27%
2024 495.558.520 -14.92%

Research and Development Expenses are the costs a company incurs to create and improve its products or services, which can be important for investors to evaluate a company's innovation and potential for future growth.

Chalkis Health Industry Co., Ltd Research and Development Expenses
Year Research and Development Expenses Growth
1997 0
1998 0 0%
1999 0 0%
2000 0 0%
2001 0 0%
2002 0 0%
2003 0 0%
2004 0 0%
2005 0 0%
2006 0 0%
2007 0 0%
2008 0 0%
2009 0 0%
2010 0 0%
2011 0 0%
2012 0 0%
2013 0 0%
2014 0 0%
2015 0 0%
2016 0 0%
2017 0 0%
2018 0 0%
2019 0 0%
2020 0 0%
2021 0 0%
2022 0 0%
2023 0 0%
2023 827.843 100%
2024 4.367.676 81.05%

General and Administrative Expenses are the costs a company incurs to run its day-to-day operations, such as office rent, salaries, and utilities, which investors consider to understand a company's overall efficiency and management effectiveness.

Chalkis Health Industry Co., Ltd General and Administrative Expenses
Year General and Administrative Expenses Growth
1997 10.400.793
1998 16.676.474 37.63%
1999 14.887.222 -12.02%
2000 19.862.377 25.05%
2001 32.640.497 39.15%
2002 38.002.739 14.11%
2003 39.027.065 2.62%
2004 47.943.201 18.6%
2005 31.982.270 -49.91%
2006 78.917.446 59.47%
2007 71.147.326 -10.92%
2008 108.827.886 34.62%
2009 81.279.942 -33.89%
2010 42.774.117 -90.02%
2011 48.889.715 12.51%
2012 60.978.132 19.82%
2013 37.708.490 -61.71%
2014 19.691.975 -91.49%
2015 14.145.091 -39.21%
2016 14.796.582 4.4%
2017 18.150.450 18.48%
2018 12.971.811 -39.92%
2019 8.443.097 -53.64%
2020 12.344.954 31.61%
2021 15.386.269 19.77%
2022 6.289.119 -144.65%
2023 92.875.226 93.23%
2023 16.758.592 -454.19%
2024 -23.104.940 172.53%

EBITDA stands for Earnings Before Interest, Taxes, Depreciation, and Amortization. It is a measure that helps stock investors analyze a company's profitability by looking at its earnings without considering certain expenses. This helps to get a clearer picture of the company's financial performance and its ability to generate cash flow.

Chalkis Health Industry Co., Ltd EBITDA
Year EBITDA Growth
1997 9.608.548
1998 34.649.387 72.27%
1999 52.545.103 34.06%
2000 58.949.445 10.86%
2001 70.435.182 16.31%
2002 105.668.578 33.34%
2003 176.573.739 40.16%
2004 199.486.867 11.49%
2005 248.379.838 19.68%
2006 197.919.588 -25.5%
2007 402.600.957 50.84%
2008 411.030.531 2.05%
2009 328.301.441 -25.2%
2010 246.198.300 -33.35%
2011 -70.759.756 447.94%
2012 704.281.838 110.05%
2013 -43.033.013 1736.61%
2014 391.757.677 110.98%
2015 146.664.009 -167.11%
2016 -7.160.851 2148.14%
2017 200.654.954 103.57%
2018 -82.098.814 344.41%
2019 17.643.758 565.31%
2020 -145.131.041 112.16%
2021 6.783.193 2239.57%
2022 167.056.488 95.94%
2023 19.462.238 -758.36%
2023 106.434.950 81.71%
2024 86.904.040 -22.47%

Gross profit is the money a company makes from selling its products or services after subtracting the cost of producing or providing them, and it is an important measure for investors to understand a company's profitability.

Chalkis Health Industry Co., Ltd Gross Profit
Year Gross Profit Growth
1997 39.255.272
1998 70.533.094 44.34%
1999 91.320.774 22.76%
2000 77.789.314 -17.4%
2001 110.485.386 29.59%
2002 159.081.545 30.55%
2003 219.664.822 27.58%
2004 234.978.366 6.52%
2005 256.511.228 8.39%
2006 257.320.872 0.31%
2007 404.340.462 36.36%
2008 490.514.780 17.57%
2009 353.667.505 -38.69%
2010 -124.983.530 382.97%
2011 27.966.218 546.91%
2012 225.879.715 87.62%
2013 108.695.823 -107.81%
2014 51.612.050 -110.6%
2015 63.129.050 18.24%
2016 49.945.566 -26.4%
2017 53.744.358 7.07%
2018 -111.910.361 148.02%
2019 12.902.790 967.33%
2020 -13.508.068 195.52%
2021 9.903.741 236.39%
2022 154.760.040 93.6%
2023 68.709.574 -125.24%
2023 133.268.023 48.44%
2024 63.846.364 -108.73%

Net income in stock investing is like the money a company actually gets to keep as profit after paying all its bills, and it's an important measure to understand how well a company is doing financially.

Chalkis Health Industry Co., Ltd Net Profit
Year Net Profit Growth
1997 4.798.214
1998 22.285.352 78.47%
1999 25.432.371 12.37%
2000 27.136.457 6.28%
2001 19.829.905 -36.85%
2002 37.561.489 47.21%
2003 82.034.661 54.21%
2004 53.262.408 -54.02%
2005 48.715.418 -9.33%
2006 -65.567.994 174.3%
2007 56.047.527 216.99%
2008 -42.160.657 232.94%
2009 27.774.854 251.79%
2010 -215.127.336 112.91%
2011 -1.151.646.490 81.32%
2012 64.021.480 1898.84%
2013 -365.679.192 117.51%
2014 11.269.942 3344.73%
2015 -48.308.583 123.33%
2016 -254.111.463 80.99%
2017 26.583.871 1055.89%
2018 -462.770.210 105.74%
2019 4.975.779 9400.46%
2020 -266.724.599 101.87%
2021 -106.874.714 -149.57%
2022 26.085.146 509.71%
2023 19.698.280 -32.42%
2023 108.237.777 81.8%
2024 23.274.932 -365.04%

EPS, or earnings per share, is a measure that shows how much profit a company has earned for each outstanding share of its stock, and it is important for stock investors as it helps understand the profitability of a company and compare it with other companies in the market.

Chalkis Health Industry Co., Ltd Earning per Share (EPS)
Year Earning per Share (EPS) Growth
1997 0
1998 0 0%
1999 0 0%
2000 0 0%
2001 0 0%
2002 0 0%
2003 0 0%
2004 0 0%
2005 0 0%
2006 0 0%
2007 0 0%
2008 0 0%
2009 0 0%
2010 0 0%
2011 -1 100%
2012 0 0%
2013 0 0%
2014 0 0%
2015 0 0%
2016 0 0%
2017 0 0%
2018 -1 0%
2019 0 0%
2020 0 0%
2021 0 0%
2022 0 0%
2023 0 0%
2023 0 0%
2024 0 0%

Cashflow Statements

Cashflow statements show the movement of money in and out of a company, helping stock investors understand how much money a company makes and spends. By examining cashflow statements, investors can assess if a company is generating enough cash to pay its bills, invest in growth, and provide returns to stockholders.

Free cash flow is the leftover cash that a company generates after covering its operating expenses and capital expenditures, which is important for stock investors as it shows how much money a company has available to invest in growth, pay dividends, or reduce debt.

Chalkis Health Industry Co., Ltd Free Cashflow
Year Free Cashflow Growth
1999 -6.209.416
2000 -364.836.677 98.3%
2001 -118.829.147 -207.03%
2002 -170.961.004 30.49%
2003 -154.165.138 -10.89%
2004 -141.442.201 -9%
2005 73.800.663 291.65%
2006 -93.741.508 178.73%
2007 61.414.640 252.64%
2008 31.457.670 -95.23%
2009 -1.103.051.176 102.85%
2010 -582.026.603 -89.52%
2011 -990.613.306 41.25%
2012 -41.611.940 -2280.6%
2013 336.407.262 112.37%
2014 -192.948.625 274.35%
2015 -340.836.776 43.39%
2016 -221.837.256 -53.64%
2017 -190.879.189 -16.22%
2018 407.701.448 146.82%
2019 142.024.518 -187.06%
2020 -13.764.404 1131.82%
2021 -200.686.314 93.14%
2022 183.660.986 209.27%
2023 -406.012.502 145.24%
2023 -398.833.844 -1.8%
2024 18.185.599 2293.13%

Operating cash flow represents the cash generated or consumed by a company's day-to-day operations, excluding external investing or financing activities, and is crucial for stock investors as it shows how much cash a company is generating from its core business operations.

Chalkis Health Industry Co., Ltd Operating Cashflow
Year Operating Cashflow Growth
1999 33.107.941
2000 -159.486.919 120.76%
2001 -35.776.913 -345.78%
2002 5.285.186 776.93%
2003 269.189.556 98.04%
2004 42.869.804 -527.92%
2005 170.476.281 74.85%
2006 65.019.714 -162.19%
2007 223.877.976 70.96%
2008 144.722.388 -54.69%
2009 -671.454.814 121.55%
2010 -428.349.936 -56.75%
2011 -905.779.556 52.71%
2012 -28.310.240 -3099.48%
2013 345.338.729 108.2%
2014 -156.063.601 321.28%
2015 -38.448.077 -305.91%
2016 -206.922.771 81.42%
2017 -176.181.921 -17.45%
2018 416.334.994 142.32%
2019 142.656.995 -191.84%
2020 -9.889.117 1542.57%
2021 -188.674.682 94.76%
2022 197.747.426 195.41%
2023 -349.099.305 156.65%
2023 -182.233.893 -91.57%
2024 28.491.830 739.6%

Capex, short for capital expenditures, refers to the money a company spends on acquiring or upgrading tangible assets like buildings, equipment, or technology, which is important for stock investors as it indicates how much a company is investing in its infrastructure to support future growth and profitability.

Chalkis Health Industry Co., Ltd Capital Expenditure
Year Capital Expenditure Growth
1999 39.317.357
2000 205.349.759 80.85%
2001 83.052.234 -147.25%
2002 176.246.190 52.88%
2003 423.354.694 58.37%
2004 184.312.005 -129.69%
2005 96.675.617 -90.65%
2006 158.761.222 39.11%
2007 162.463.336 2.28%
2008 113.264.718 -43.44%
2009 431.596.362 73.76%
2010 153.676.667 -180.85%
2011 84.833.750 -81.15%
2012 13.301.701 -537.77%
2013 8.931.467 -48.93%
2014 36.885.024 75.79%
2015 302.388.699 87.8%
2016 14.914.485 -1927.48%
2017 14.697.268 -1.48%
2018 8.633.546 -70.23%
2019 632.476 -1265.04%
2020 3.875.287 83.68%
2021 12.011.632 67.74%
2022 14.086.440 14.73%
2023 56.913.198 75.25%
2023 216.599.951 73.72%
2024 10.306.231 -2001.64%

Balance Sheet

Balance sheets provide a snapshot of a company's financial health and its assets (such as cash, inventory, and property) and liabilities (like debts and obligations) at a specific point in time. For stock investors, balance sheets help assess the company's overall worth and evaluate its ability to meet financial obligations and support future growth.

Equity refers to the ownership interest or stake that shareholders have in a company, representing their claim on its assets and earnings after all debts and liabilities are paid.

Chalkis Health Industry Co., Ltd Equity
Year Equity Growth
1997 28.884.111
1998 162.115.209 82.18%
1999 180.970.697 10.42%
2000 425.348.683 57.45%
2001 456.115.313 6.75%
2002 496.496.618 8.13%
2003 578.358.582 14.15%
2004 628.091.980 7.92%
2005 870.505.815 27.85%
2006 1.272.961.955 31.62%
2007 1.329.446.396 4.25%
2008 1.561.145.799 14.84%
2009 1.199.507.490 -30.15%
2010 1.387.133.126 13.53%
2011 71.868.469 -1830.1%
2012 217.629.353 66.98%
2013 -254.885.403 185.38%
2014 767.556.458 133.21%
2015 1.030.435.337 25.51%
2016 760.279.052 -35.53%
2017 880.705.919 13.67%
2018 442.872.396 -98.86%
2019 447.935.787 1.13%
2020 181.211.189 -147.19%
2021 74.336.475 -143.77%
2022 100.421.093 25.98%
2023 209.455.997 52.06%
2023 143.586.096 -45.87%
2024 228.272.414 37.1%

Assets represent the valuable resources that a company owns, such as cash, inventory, property, and equipment, and understanding a company's assets helps investors assess its value and potential for generating future profits.

Chalkis Health Industry Co., Ltd Assets
Year Assets Growth
1997 183.144.141
1998 440.986.352 58.47%
1999 587.021.441 24.88%
2000 1.038.766.878 43.49%
2001 1.229.122.436 15.49%
2002 1.410.361.748 12.85%
2003 1.918.146.763 26.47%
2004 2.423.080.687 20.84%
2005 3.497.134.682 30.71%
2006 4.221.861.740 17.17%
2007 4.843.361.303 12.83%
2008 5.556.776.128 12.84%
2009 5.609.182.522 0.93%
2010 5.521.476.386 -1.59%
2011 4.450.166.866 -24.07%
2012 3.726.162.937 -19.43%
2013 2.705.446.225 -37.73%
2014 1.971.019.546 -37.26%
2015 2.629.834.559 25.05%
2016 2.412.637.151 -9%
2017 2.347.205.366 -2.79%
2018 1.226.692.417 -91.34%
2019 740.282.440 -65.71%
2020 582.505.841 -27.09%
2021 676.041.526 13.84%
2022 825.364.850 18.09%
2023 1.224.071.923 32.57%
2023 1.426.861.708 14.21%
2024 1.162.244.409 -22.77%

Liabilities refer to the financial obligations or debts that a company owes to creditors or external parties, and understanding a company's liabilities is important for investors as it helps assess the company's financial risk and ability to meet its obligations.

Chalkis Health Industry Co., Ltd Liabilities
Year Liabilities Growth
1997 154.260.029
1998 278.871.142 44.68%
1999 406.050.743 31.32%
2000 613.418.193 33.81%
2001 773.007.122 20.65%
2002 913.865.129 15.41%
2003 1.339.788.180 31.79%
2004 1.794.988.705 25.36%
2005 2.626.628.866 31.66%
2006 2.948.899.784 10.93%
2007 3.513.914.906 16.08%
2008 3.995.630.328 12.06%
2009 4.409.675.031 9.39%
2010 4.134.343.259 -6.66%
2011 4.378.298.396 5.57%
2012 3.508.533.583 -24.79%
2013 2.960.331.627 -18.52%
2014 1.203.463.087 -145.98%
2015 1.599.399.221 24.76%
2016 1.652.358.098 3.21%
2017 1.466.499.445 -12.67%
2018 783.820.020 -87.1%
2019 292.346.652 -168.11%
2020 401.294.652 27.15%
2021 601.705.050 33.31%
2022 724.943.756 17%
2023 997.716.401 27.34%
2023 1.283.275.612 22.25%
2024 916.343.899 -40.04%

Chalkis Health Industry Co., Ltd Financial Ratio (TTM)

Valuation Metrics

Revenue per Share
0.68
Net Income per Share
0.11
Price to Earning Ratio
28.33x
Price To Sales Ratio
4.39x
POCF Ratio
-10.97
PFCF Ratio
-6.29
Price to Book Ratio
10.78
EV to Sales
5.02
EV Over EBITDA
43.62
EV to Operating CashFlow
-12.54
EV to FreeCashFlow
-7.19
Earnings Yield
0.04
FreeCashFlow Yield
-0.16
Market Cap
2,32 Bil.
Enterprise Value
2,65 Bil.
Graham Number
0.82
Graham NetNet
-0.65

Income Statement Metrics

Net Income per Share
0.11
Income Quality
-2.58
ROE
0.43
Return On Assets
0.07
Return On Capital Employed
0.12
Net Income per EBT
0.98
EBT Per Ebit
2.05
Ebit per Revenue
0.08
Effective Tax Rate
0.01

Margins

Sales, General, & Administrative to Revenue
0.03
Research & Developement to Revenue
0
Stock Based Compensation to Revenue
0
Gross Profit Margin
0.19
Operating Profit Margin
0.08
Pretax Profit Margin
0.16
Net Profit Margin
0.16

Dividends

Dividend Yield
0
Dividend Yield %
0
Payout Ratio
0.29
Dividend Per Share
0

Operating Metrics

Operating Cashflow per Share
-0.27
Free CashFlow per Share
-0.48
Capex to Operating CashFlow
-0.74
Capex to Revenue
0.3
Capex to Depreciation
35.43
Return on Invested Capital
0.06
Return on Tangible Assets
0.07
Days Sales Outstanding
67.06
Days Payables Outstanding
66.86
Days of Inventory on Hand
412.32
Receivables Turnover
5.44
Payables Turnover
5.46
Inventory Turnover
0.89
Capex per Share
0.2

Balance Sheet

Cash per Share
0,13
Book Value per Share
0,32
Tangible Book Value per Share
0.3
Shareholders Equity per Share
0.28
Interest Debt per Share
0.59
Debt to Equity
2
Debt to Assets
0.37
Net Debt to EBITDA
5.46
Current Ratio
0.88
Tangible Asset Value
0,23 Bil.
Net Current Asset Value
-0,19 Bil.
Invested Capital
338522760
Working Capital
-0,10 Bil.
Intangibles to Total Assets
0.01
Average Receivables
0,07 Bil.
Average Payables
0,08 Bil.
Average Inventory
517176563.5
Debt to Market Cap
0.19

Dividends

Dividends in stock investing are like rewards that companies give to their shareholders. They are a portion of the company's profits distributed to investors, typically in the form of cash payments, as a way for them to share in the company's success.

Chalkis Health Industry Co., Ltd Dividends
Year Dividends Growth
2001 0
2002 0 0%
2003 0 0%
2004 0 0%
2005 0 0%
2006 0 0%
2007 0 0%
2008 0 0%

Chalkis Health Industry Co., Ltd Profile

About Chalkis Health Industry Co., Ltd

Chalkis Health Industry Co., Ltd. produces, processes, and sells tomatoes worldwide. It offers tomato paste concentrated in drums and wooden bins, peeled and diced tomatoes, canned tomato products, tomato fiber sheets, and tomato seed oil, as well as lycopene capsules. The company was formerly known as Xinjiang Chalkis Co., Ltd. and changed its name to Chalkis Health Industry Co., Ltd. in May 2016. Chalkis Health Industry Co., Ltd. is based in Urumqi, China.

CEO
Mr. Wen Bo Mao
Employee
585
Address
No. 2666, Courtyard Room Hotel
Wujiaqu,

Chalkis Health Industry Co., Ltd Executives & BODs

Chalkis Health Industry Co., Ltd Executives & BODs
# Name Age
1 Mr. Wen Bo Mao
GM & Director
70
2 Mr. Yanxun Zhuang
Deputy GM & Director
70
3 Ms. Ye Li
Deputy General Manager
70
4 Mr. Jiang Xing
Secretary of the Board of Directors & Deputy GM
70
5 Ms. Shanshan Chang
Financial Director & Deputy GM
70

Chalkis Health Industry Co., Ltd Competitors